Navigation Links
Women Faces No Risk on Discontinuation of Osteoporosis Drug

A long-term study of the most widely used osteoporosis drug has found that many women can discontinue //the drug after five years without increasing their fracture risk for as long as five more years.

The study on alendronate was led by researchers at the University of California, San Francisco. The research also showed that women at very high risk of painful spine fractures might be better-off continuing treatment.

"This has important implications as it has not been known whether treatment of osteoporosis should be continued indefinitely," said lead author Dennis Black, PhD, professor in the UCSF Department of Epidemiology and Biostatistics. "Because women with osteoporosis, particularly older post-menopausal women, often need to take multiple drugs, this would be welcome news for this group."

According to Black, shorter term studies of up to five years duration have shown reductions in fracture risk with alendronate treatment. This was the first study to examine the effects on fracture using the drug longer than five years, he said.

"We found that women who discontinued the drug had the same rate of non-spine fractures as women who continued using the drug," he said. "However, for clinically-recognized spine fractures, usually discovered due to back pain, continuing alendronate was better than discontinuing. And, if women choose to continue, we showed that 10 years of treatment is safe."

The new findings are from a follow-up study to the initial randomized trial that examined the effect of daily alendronate, a bisphosphonate or anti-resorptive drug, on bone mineral density and fracture risk in post-menopausal women with low BMD for up to 3.8 years.

Alendronate is used to reduce bone loss, increase bone density and reduce the risk of spine, wrist and hip fractures in postmenopausal women. Bisphosphonates are the most commonly used treatment for postmenopausal osteoporosis.

The ini
'"/>




Page: 1 2 3

Related medicine news :

1. Women suffer from sexual dysfunction too
2. Women find difficulty in calling it Quits
3. Women recognise faces better
4. Women more susceptible to brain damage from ecstasy
5. Good News For Women With Gestational Diabetes
6. Unsatisfactory Grade On Womens Health Issues
7. Risk for Pregnant Women
8. Womens strong sense of smell
9. Women need to exercise more to prevent obesity
10. Women benefit from consuming fish
11. Women are at risk with raised cholesterol
Post Your Comments:
Other Medicine News:Health News:UK Physicians Fear New Revalidation Procedures Will Reduce Morale, Decrease Time with Patients and Belittle GP Professionalism, According to New TNS Healthcare Research 2Health News:UK Physicians Fear New Revalidation Procedures Will Reduce Morale, Decrease Time with Patients and Belittle GP Professionalism, According to New TNS Healthcare Research 3Health News:UK Physicians Fear New Revalidation Procedures Will Reduce Morale, Decrease Time with Patients and Belittle GP Professionalism, According to New TNS Healthcare Research 4Health News:Researchers unveil vital key to cancer 2Health News:Hospira Reports Second-Quarter 2008 Results 2Health News:Hospira Reports Second-Quarter 2008 Results 3Health News:Hospira Reports Second-Quarter 2008 Results 4Health News:Hospira Reports Second-Quarter 2008 Results 5Health News:Hospira Reports Second-Quarter 2008 Results 6Health News:Hospira Reports Second-Quarter 2008 Results 7Health News:Hospira Reports Second-Quarter 2008 Results 8Health News:Hospira Reports Second-Quarter 2008 Results 9Health News:Hospira Reports Second-Quarter 2008 Results 10Health News:Hospira Reports Second-Quarter 2008 Results 11Health News:Hospira Reports Second-Quarter 2008 Results 12Health News:Hospira Reports Second-Quarter 2008 Results 13Health News:Hospira Reports Second-Quarter 2008 Results 14Health News:Hospira Reports Second-Quarter 2008 Results 15Health News:Hospira Reports Second-Quarter 2008 Results 16Health News:Hospira Reports Second-Quarter 2008 Results 17Health News:Hospira Reports Second-Quarter 2008 Results 18Health News:Hospira Reports Second-Quarter 2008 Results 19Health News:Hospira Reports Second-Quarter 2008 Results 20Health News:Hospira Reports Second-Quarter 2008 Results 21Health News:Hospira Reports Second-Quarter 2008 Results 22Health News:Hospira Reports Second-Quarter 2008 Results 23Health News:Hospira Reports Second-Quarter 2008 Results 24Health News:Hospira Reports Second-Quarter 2008 Results 25Health News:Hospira Reports Second-Quarter 2008 Results 26Health News:Hospira Reports Second-Quarter 2008 Results 27Health News:Hospira Reports Second-Quarter 2008 Results 28Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 2Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 3Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 4Health News:Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008 5
Breaking Medicine Technology:BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 1Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 2Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 3American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 55925 1American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 55925 2Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 1Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 2Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 3
Other Medicine Technology:Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 2Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 3Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 4Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 5Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4